MKI67 and neoplasm: Therefore, therapeutic decision-making process is still commonly based on clinical and immunohistochemical (IHC) characteristics, namely tumor size and grade, nodal status, hormone receptor (HR) expression, human epidermal growth factor receptor 2 (HER2) status and Ki67 values (3).